TITLE

New drug and biological product approvals, 2007

AUTHOR(S)
Traynor, Kate
PUB. DATE
February 2008
SOURCE
American Journal of Health-System Pharmacy;2/1/2008, Vol. 65 Issue 3, p190
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article offers news briefs related to drug approvals in the U.S. for 2008. The marketing of maraviroc, a chemokine receptor 5 (CCR5) blocker, was approved by the Food and Drug Administration (FDA) in August 2007. The FDA gave approval for three products intended for the treatment of advanced forms of cancer. Sanofi's H5N1 vaccine and ACAM2000 were made to plug holes in the nation's biodefense and preparedness programs and are not available to the general public.
ACCESSION #
31142344

 

Related Articles

  • FDA Approves First US Avian Influenza Virus Vaccine.  // Pulmonary Reviews;May2007, Vol. 12 Issue 5, p14 

    The article reports on the approval of the first avian influenza virus vaccine for humans by the U.S. Food and Drug Administration. The vaccine manufactured by Sanofi Pasteur Inc. was obtained from a human strain and is intended for immunizing people 18 through 64 years of age at risk of...

  • IN BRIEF.  // BMJ: British Medical Journal (International Edition);4/28/2007, Vol. 334 Issue 7599, p868 

    This article presents medical news briefs. The United States Food and Drug Administration has approved a human vaccine against the H5N1 influenza virus (bird flu). Medical Research Scotland is inviting applications for research projects on pain relief. Public prosecutors in the Netherlands have...

  • Targeting the hypoxia-adenosinergic signaling pathway to improve the adoptive immunotherapy of cancer. Sitkovsky, Michail; Ohta, Akio // Journal of Molecular Medicine;Feb2013, Vol. 91 Issue 2, p147 

    The recent approval by the FDA of cancer vaccines and drugs that blockade immunological negative regulators has further enhanced interest in promising approaches of the immunotherapy of cancer. However, the disappointingly short life extension has also underscored the need to better understand...

  • Menactra available for young children; FDA approves vandetanib. Coleman, Craig I. // Drug Topics;Jul2011, Vol. 155 Issue 7, p38 

    The article offers information on the efficacy of Menactra, a quadrivalent meningococcal vaccine, for young children and the approval of vandetanib, an oral kinase inhibitor, by the U.S. Food and Drug Association (FDA). It notes that Menactra showed significant immune response against...

  • FDA approves new drug to help cancer patients.  // R&D Magazine;Apr2003, Vol. 45 Issue 4, p41 

    Reports on the approval by the U.S. Food and Drug Administration of the drug Emend, which is used in combination with other anti-nausea and anti-vomiting drugs for prevention of acute nausea and vomiting associated with chemotherapy. Benefits of the drug on cancer patient's quality of life;...

  • Lymphoseek approved to locate lymph nodes in breast cancer, melanoma.  // Hem/Onc Today;4/10/2013, Vol. 14 Issue 7, p15 

    The article reports on the approval given by the U.S. Food and Drug Administration (FDA) to technetium Tc 99m tilmanocept to help in the location of lymph nodes in patients with breast cancer or melanoma.

  • New Treatment for Advanced Breast Cancer.  // Clarendon Enterprise (TX);11/1/2007, Vol. 18 Issue 46, p7 

    The article reports that the Food and Drug Administration (FDA) has approved the Ixempera, a new treatment for advanced breast cancer in the U.S.

  • FDA approves Xofiqo for metastatic prostate cancer.  // Hem/Onc Today;6/25/2013, Vol. 14 Issue 12, p24 

    The article reports on the approval by the U.S. Food and Drug Administration (FDA) of radium Ra 223 dichloride as a treatment for men with metastatic castration-resistant prostate cancer.

  • Tarceva approved for first-line treatment of NSCLC.  // Hem/Onc Today;6/10/2013, Vol. 14 Issue 11, p47 

    The article reports that erlotinib was approved by the U.S. Food and Drug Administration as a first-line treatment for patients with metastatic non-small cell lung cancer.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics